Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF LEVOSIMENDAN IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION UNDERGOING CARDIAC SURGERY REQUIRING CARDIOPULMONARY BYPASS; LEVO-CTS

Intervention/treatment:
SIMDAX (LEVOSIMENDAN)
Medical condition:
CARDIAC SURGERY
Protocol code:
TNX-LVO-01
Control number:
181096
Status:
Closed
Approved:
February 04, 2015
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02025621
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Rajendra Mehta, MD Study Principal Investigator
Organization
Duke Clinical Research Institute
Phone:
919-668-8971
Sponsor
TENAX THERAPEUTICS INC

Locations

Alberta

University of Alberta Hospital
Edmonton, Alberta

British Columbia

Royal Jubilee Hospital (Vancouver Island Health Authority)
Victoria, British Columbia
Victoria Heart Institute Foundation
Victoria, British Columbia

Manitoba

St. Boniface Hospital
Winnepeg, Manitoba

Ontario

Hamilton Health Sciences
Hamilton, Ontario
Institute universitaire de cardiologie et pneumologie de Quebec
Québec, Ontario
London Health Sciences Center, University Hospital
London, Ontario
Southlake Regional Health Center
Newmarket, Ontario
St. Michael's Hospital
Toronto, Ontario

Quebec

McGill University Health Centre-Royal Victoria Hospital
Montreal, Quebec
Montreal Heart Institute
Montreal, Quebec

Results

See the results from the trial NCT02025621. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?